Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
Joshua Schimmer is an analyst at Cantor Fitzgerald. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 03/19/2025
| Buy Now | Get Alert | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 04/05/2024 | CABA | Buy Now | Cabaletta Bio | $1.83 | 2632.24% | Joshua Schimmer43% | $50 → $50 | Reiterates | Overweight → Overweight | Get Alert |
| 03/22/2024 | CABA | Buy Now | Cabaletta Bio | $1.83 | 2632.24% | Joshua Schimmer43% | $50 → $50 | Reiterates | Overweight → Overweight | Get Alert |
| 11/15/2023 | MIRM | Buy Now | Mirum Pharmaceuticals | $47.13 | 6.09% | Joshua Schimmer43% | → $50 | Reiterates | Overweight → Overweight | Get Alert |
| 11/15/2023 | CABA | Buy Now | Cabaletta Bio | $1.83 | 2632.24% | Joshua Schimmer43% | $40 → $50 | Maintains | Overweight | Get Alert |
| 10/24/2023 | MIRM | Buy Now | Mirum Pharmaceuticals | $47.13 | 6.09% | Joshua Schimmer43% | → $50 | Initiates | → Overweight | Get Alert |
| 10/24/2023 | CABA | Buy Now | Cabaletta Bio | $1.83 | 2085.79% | Joshua Schimmer43% | → $40 | Initiates | → Overweight | Get Alert |
| 07/27/2023 | OTIS | Buy Now | Otis Worldwide | $102.77 | -10.48% | Joshua Schimmer43% | $91 → $92 | Maintains | Equal-Weight | Get Alert |
| 07/12/2023 | OTIS | Buy Now | Otis Worldwide | $102.77 | -11.45% | Joshua Schimmer43% | $91 → $91 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 04/27/2023 | OTIS | Buy Now | Otis Worldwide | $102.77 | -11.45% | Joshua Schimmer43% | $90 → $91 | Maintains | Equal-Weight | Get Alert |
| 04/19/2023 | OTIS | Buy Now | Otis Worldwide | $102.77 | -12.43% | Joshua Schimmer43% | $89 → $90 | Maintains | Equal-Weight | Get Alert |
| 03/31/2023 | RNA | Buy Now | Avidity Biosciences | $31.72 | -36.95% | Joshua Schimmer43% | → $20 | Downgrade | Outperform → In-Line | Get Alert |
| 03/13/2023 | SGEN | Buy Now | Seagen | — | — | Joshua Schimmer43% | $175 → $229 | Downgrade | Outperform → In-Line | Get Alert |
| 03/10/2023 | BNOX | Buy Now | Bionomics | — | — | Joshua Schimmer43% | → $6 | Upgrade | In-Line → Outperform | Get Alert |
| 03/03/2023 | NBIX | Buy Now | Neurocrine Biosciences | $109.71 | 18.49% | Joshua Schimmer43% | → $130 | Upgrade | In-Line → Outperform | Get Alert |
| 02/28/2023 | DNLI | Buy Now | Denali Therapeutics | $14.82 | 237.38% | Joshua Schimmer43% | $80 → $50 | Maintains | Outperform | Get Alert |
| 01/24/2023 | TGTX | Buy Now | TG Therapeutics | $42.61 | -41.33% | Joshua Schimmer43% | $16 → $25 | Maintains | Outperform | Get Alert |
| 12/30/2022 | TGTX | Buy Now | TG Therapeutics | $42.61 | -62.45% | Joshua Schimmer43% | $11 → $16 | Maintains | Outperform | Get Alert |
| 12/20/2022 | BNOX | Buy Now | Bionomics | — | — | Joshua Schimmer43% | $17 → $6 | Downgrade | Outperform → In-Line | Get Alert |
| 10/26/2022 | MYOV | Buy Now | Myovant Sciences | — | — | Joshua Schimmer43% | → $27 | Downgrade | Outperform → In-Line | Get Alert |
| 09/30/2022 | RCKT | Buy Now | Rocket Pharmaceuticals | $8.46 | 786.52% | Joshua Schimmer43% | $65 → $75 | Maintains | Outperform | Get Alert |
| 12/01/2021 | TGTX | Buy Now | TG Therapeutics | $42.61 | -15.51% | Joshua Schimmer43% | $55 → $36 | Maintains | Outperform | Get Alert |
| 03/01/2021 | BMRN | Buy Now | Biomarin Pharmaceutical | $71.32 | 40.21% | Joshua Schimmer43% | $90 → $100 | Upgrade | In-Line → Outperform | Get Alert |
| 02/25/2020 | REGN | Buy Now | Regeneron Pharmaceuticals | $672.36 | — | Joshua Schimmer43% | — | Upgrade | In-Line → Outperform | Get Alert |
| 02/03/2020 | BLUE | Buy Now | bluebird bio | $3.99 | 2407.46% | Joshua Schimmer43% | $1720 → $2000 | Upgrade | In-Line → Outperform | Get Alert |
| 12/16/2019 | REGN | Buy Now | Regeneron Pharmaceuticals | $672.36 | — | Joshua Schimmer43% | — | Downgrade | Outperform → In-Line | Get Alert |
| 11/19/2019 | BLUE | Buy Now | bluebird bio | $3.99 | 2056.42% | Joshua Schimmer43% | → $1720 | Downgrade | Outperform → In-Line | Get Alert |
| 05/31/2018 | INCY | Buy Now | Incyte | $60.34 | 40.87% | Joshua Schimmer43% | → $85 | Assumes | → Overweight | Get Alert |
| 01/23/2018 | BIVV | Buy Now | Bioverativ | — | — | Joshua Schimmer43% | — | Downgrade | Overweight → Neutral | Get Alert |
| 10/27/2017 | GEMP | Buy Now | Gemphire Therapeutics | — | — | Joshua Schimmer43% | → $550 | Assumes | → Overweight | Get Alert |
| 10/23/2017 | BIVV | Buy Now | Bioverativ | — | — | Joshua Schimmer43% | → $71 | Assumes | Overweight → Overweight | Get Alert |
| 04/17/2017 | INCY | Buy Now | Incyte | $60.34 | 105.5% | Joshua Schimmer43% | → $124 | Downgrade | Overweight → Neutral | Get Alert |
| 04/10/2017 | GEMP | Buy Now | Gemphire Therapeutics | — | — | Joshua Schimmer43% | → $750 | Initiates | → Overweight | Get Alert |
| 02/28/2017 | BIVV | Buy Now | Bioverativ | — | — | Joshua Schimmer43% | — | Upgrade | Neutral → Overweight | Get Alert |
| 11/26/2013 | INCY | Buy Now | Incyte | $60.34 | — | Joshua Schimmer43% | — | Assumes | → Overweight | Get Alert |
